Previous 10 | Next 10 |
2024-01-25 12:12:13 ET Summary NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program. NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of ...
2024-01-19 10:47:56 ET More on Nkarta Nkarta: Trying To Be The NK Story That Actually Succeeds Seeking Alpha’s Quant Rating on Nkarta Historical earnings data for Nkarta Financial information for Nkarta For further details see: Nkarta says ...
2024-01-09 10:25:55 ET Palm Beach, FL – January 9, 2024 – According to the report titled “Aging in the United States,” published by the Population Reference Bureau, “the number of Americans aged 65 and older is projected to increase more than double over 9...
2024-01-08 16:53:20 ET Gainers: Universe Pharmaceuticals ( UPC ) +13% . MaxCyte ( MXCT ) +12% . WISeKey International Holding ( WKEY ) +8% . Alset Capital Acquisition ( ACAX ) +7% . Atea Pharmaceuticals ( AVIR ) +...
2023-12-23 07:00:00 ET More on Carvana Carvana: Kicking The Can Down The Road Carvana's Controversial Journey: Why I'm Still Bullish Despite Debt Exchange, Carvana Is Still Not A Buy Auto retail stocks gain after better-than-feared earnings report from CarMax...
2023-12-19 16:50:11 ET Gainers: Shimmick Corporation ( SHIM ) +11% . Westport Fuel Systems ( WPRT ) +5% . Telos Corporation ( TLS ) +2% . NN ( NNBR ) +2% . CureVac ( CVAC ) +2% . Losers: Guardant Health ( GH...
2023-12-19 10:11:12 ET Penny Stocks and Preparing for 2024 As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023’s ups and downs; maybe not. For those interested in penny stocks, the high-risk but potentially...
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting an...
2023-12-03 07:44:31 ET Summary Nkarta is a biotech company developing cell therapies for cancer and autoimmune disease. Their lead programs focus on harnessing the potential of targeted natural killer (NK) cells to fight tumors and microbes. The company has a strong cash pool ...
2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...